- The FDA has approved Allergan and AbbVie Inc's (NYSE: ABBV) BOTOX (onabotulinumtoxinA). It is used to treat detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients five years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.
- Neurogenic detrusor overactivity occurs when the spinal cord and bladder are not able to communicate effectively. As a result, the bladder muscle involuntarily contracts, increasing the bladder's pressure and reducing the bladder capacity, which can cause the individual to leak urine frequently and unexpectedly.
- Price Action: ABBV share are down 0.68% at $104.68 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
